<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals has filed a mandatory disclosure with BSE and NSE confirming it does not qualify as a 'Large Corporate' under SEBI regulations as of March 31, 2026. The company reported outstanding borrowings of Rs. 54.07 crores (un-audited) as of March 31, 2025. No credit rating was applicable for the previous financial year 2024-25. This filing follows SEBI's requirement that entities must confirm their Large Corporate status even if they do not fall under that category. The disclosure is signed by Company Secretary Vinay Kumar Mishra and CFO Deval Rajnikant Shah.
This is a routine regulatory compliance filing with no direct impact on shareholders or stock price. The company confirms it remains below the threshold for Large Corporate classification despite having some debt exposure.